On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo.

There were no serious safety concerns identified. Through the NIAID-funded INSIGHT network, the study team enrolled nearly 600 adult patients at 63 sites in the U.S. and 10 other countries on five continents.